Novel GM-CSF-based vaccines: One small step in GM-CSF gene optimization, one giant leap for human vaccines

Hum Vaccin Immunother. 2016 Dec;12(12):3020-3028. doi: 10.1080/21645515.2016.1221551. Epub 2016 Aug 25.

Abstract

Granulocyte macrophage-colony stimulating factor (GM-CSF) is a potent immunomodulatory cytokine that is known to facilitate vaccine efficacy by promoting the development and prolongation of both humoral and cellular immunity. In the past years we have generated a novel codon-optimized GM-CSF gene as an adjuvant. The codon-optimized GM-CSF gene significantly increased protein expression levels in all cells tested and helped in generating a strong immune responses against HIV-1 Gag and HPV-associated cancer. Here, we review the literature dealing with the adjuvant activity of GM-CSF both in animal models and clinical trials. We anticipate that the codon-optimized GM-CSF gene offers a practical molecular strategy for potentiating immune responses to tumor cell-based vaccinations as well as other immunotherapeutic strategies.

Keywords: GM-CSF; cancer vaccine; cytotoxic T cells; immunotherapy.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS Vaccines / administration & dosage
  • AIDS Vaccines / immunology*
  • Adjuvants, Immunologic / administration & dosage*
  • Adjuvants, Immunologic / genetics
  • Animals
  • Cancer Vaccines / administration & dosage
  • Cancer Vaccines / immunology*
  • Clinical Trials as Topic
  • Drug Evaluation, Preclinical
  • Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage*
  • Granulocyte-Macrophage Colony-Stimulating Factor / genetics
  • Humans
  • Models, Animal

Substances

  • AIDS Vaccines
  • Adjuvants, Immunologic
  • Cancer Vaccines
  • Granulocyte-Macrophage Colony-Stimulating Factor